Sign in Register

Synribo (omacetaxine mepesuccinate)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Generic name: omacetaxine mepesuccinate

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Synribo

Intelligence content is not available yet.

Indications

The following indications are listed for Synribo:

  • Accelerated Phase Chronic Myelocytic Leukemia
  • Chronic Phase Chronic Myeloid Leukemia

Also known as: Chronic Granulocytic Leukemia In Accelerated Phase, Chronic Leukemic Myelosis In Accelerated Phase, Chronic Myelogenic Leukemia In Accelerated Phase, Chronic Myelogenous Leukemia Chronic Phase, Chronic Myelogenous Leukemia In Accelerated Phase, Chronic Myeloid Leukemia In Accelerated Phase, Cml Accelerated Phase, Cml Chronic Phase.

Dosing

No dosing information is available for this tab.

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a 5-digit ZIP code. Searching does not change your profile.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data